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Summary Nitrous oxide (N20) inactivates the vitamin B12-dependent enzyme methionine synthetase with
subsequent impairment of folate metabolism and a reduction of cellular proliferation. Indications exist that
this effect is antagonized by S-adenosylmethionine (SAM), and it was investigated whether combination with
an inhibitor of SAM synthesis, cycloleucine, would result in increased inhibition of growth in rat leukaemia
model (BNML). Leukaemic growth was compared in untreated rats, in rats treated with either nitrous
oxide/oxygen (1:1) or cycloleucine (50mgkg-1 i.p.), and in rats receiving both agents. Combined treatment
resulted in the strongest reduction of leukaemic infiltration in spleen and liver, and this reduction often was
more than the added effects of single treatments. Peripheral leukocyte counts were also lowest after combined
treatment. The deoxyuridine suppression test, measuring folate-dependent de novo synthesis of thymidine, was
more severely disturbed with combined treatment. Levels of vitamin B12 in plasma were reduced in rats
receiving N20, but an increase in plasma folate occurred in all treated rats. These results indicate that a
reduction of SAM synthesis by cycloleucine can increase the disturbance of folate metabolism that is caused
by nitrous oxide, with a potentiation of the effects on leukaemic growth.
The well known anaesthetic gas nitrous oxide
(N20) is able to suppress haematopoiesis, giving
rise to megaloblastic anaemia in man (Lassen et al.,
1956) and marked leukopenia in rats (Green &
Eastwood, 1963; Parbrook, 1967; Johnson et al.,
1971). This effect could be explained by a specific
oxidative action of nitrous oxide on the cobalt-
moiety of vitamin B12 (Amess et al., 1978), which
causes a nearly complete inactivation of the methyl-
cobalamin-requiring enzyme methionine synthetase
or 5-methyltetrahydrofolate homocysteine methyl-
transferase (E.C. 2.1.1.13). This results in a
decreased availability of tetrahydrofolate
coenzymes, which impairs folate dependent de novo
synthesis of thymidine and ultimately affects
cellular proliferation. Attempts to utilize this
haematological side effect of nitrous oxide in the
treatment of human leukaemia were already
reported before its biochemical mechanism was
revealed (Lassen & Kristensen, 1959; Eastwood et
al., 1963). These preliminary trials showed some
promising results with a rapid, though reversible,
regression of leukaemia on nitrous oxide exposure.
Recent investigations have confirmed inhibition of
tumour growth in vitro, in several human cell lines
(Kano et al., 1983), and in vivo, in leukaemic rats
(Kroes et al., 1984).
The use of nitrous oxide in metabolic studies
made clear that the effects of this agent, through a
reduction of methionine supply, also involve a
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decreased synthesis of S-adenosylmethionine (SAM)
(Lumb et al., 1983; Makar & Tephly, 1983). In
addition, it appeared that SAM antagonized the
disturbance of folate metabolism which is caused by
nitrous oxide (Eells et al., 1982; Sourial & Amess,
1983). These observations suggest that a further
reduction of SAM might enhance the inhibiting
effects of nitrous oxide on cellular proliferation.
We now report the effect of combining nitrous
oxide with cycloleucine (NSC-1026, 1-aminocyclo-
pentane carboxylic acid). Cycloleucine is a potent
inhibitor of the enzyme methionine adenosyl-
transferase (E.C. 2.5.1.6.) (Lombardini et al., 1970),
which converts methionine into SAM. The
combined action of nitrous oxide and cycloleucine
can cause a sequential blockade of SAM synthesis,
possibly resulting in increased inhibition of tumour
growth. Interestingly, cycloleucine by itself also has
cytostatic properties (Connors et al., 1960; Ross et
al., 1961). However, in recent clinical trials this
drug, in high doses, was unsuccessful mainly
because of severe neurological and haematological
toxicity (Savlov et al., 1981; Dindogru et al., 1982).
This study describes the effects of nitrous oxide
exposure, combined with the administration of
cycloleucine, on proliferation of an experimental
rat leukaemia: the Brown Norway Myeloid
Leukaemia (BNML). This transplantable leukaemia
has been described in detail (Hagenbeek & Van
Bekkum, 1977) and is considered to be a suitable
model for experimental chemotherapy (Van
Bekkum & Hagenbeek, 1977). To evaluate the
metabolic effects of vitamin B12-inactivation by
nitrous oxide, the deoxyuridine suppression test is
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used, and plasma levels are determined of vitamin
B12 and folic acid.
Materials and methods
Animals
Male rats of the Brown Norway inbred strain were
used, at the age of 14-18 weeks (body wt. 200-
290g). Food and water were supplied ad libitum
during the experiments.
Brown Norway myelocytic leukaemia (BNML)
Cryopreserved leukaemic cells were kindly provided
by Dr A. Hagenbeek from the Radiobiological
Institute TNO, Rijswijk, the Netherlands, where this
transplantable rat leukaemia model was developed.
Origin, classification and proliferation kinetics were
described before (Hagenbeek & Van Bekkum,
1977). For leukaemia transfer in experimental
series, spleen cells of fully leukaemic animals were
used. 107 cells, suspended in 1 ml of Hanks
balanced salt solution were injected i.v. This
standard dose leads to death in 20-24 days. During
this period massive leukaemic infiltration of spleen,
liver and bone marrow takes place. Spleen and liver
weights, therefore, are reliable indicators of tumour
load and, along with haematological deter-
minations, can be used effectively to assess the
effects of chemotherapy, correlating well with
studies of survival time (Hagenbeek & Van
Bekkum, 1977). To avoid a gradual change in
growth properties, serial transplantations were
limited to only two passages in order, after which
spleen cells were used from animals of a separate
series, freshly inoculated with cells from a
cryopreserved stock.
Treatment with nitrous oxide and cycloleucine
Two sets of identical experiments were carried out
separately (Experiments 1 and 2). In each, 4 groups
of 4 rats were inoculated with leukaemic cells at
Day 0. Mean body weight in each group was nearly
identical. Treatment of these leukaemic rats started
at Day 7. To detect any synergistic action, one
group received no treatment (controls), while the
other 3 groups were treated with nitrous oxide,
cycloleucine, or both. Rats were exposed to nitrous
oxide in a 361 flow chamber, in which a mixture of
50% nitrous oxide and 50% oxygen was blown at a
rate of about 1000mlmin-1. Oxygen concentration
was monitored with an oxygen analyzer (Teledyne
Analytical Instruments). Exposure was interrupted
only for short cleaning periods. Rats not exposed to
N20 were kept in air, but otherwise treated
identically. Cycloleucine was administered as a
single i.p. injection at Day 7, of 50mgkg-1
cycloleucine (Sigma Chemical Co., St Louis, USA),
dissolved in water containing 0.15moll-1 NaCl.
Rats not receiving cycloleucine were injected with
0.15mol 1 NaCl solution i.p.
Evaluation oftreatment
To allow a simultaneous investigation of several
parameters of leukaemic growth, including
metabolic tests, both experiments were terminated
after a fixed period of 19 days of leukaemia, which
is just before the rats would die spontaneously.
Rats were killed by exsanguination under either
anaesthesia, after recording their body weights.
Liver and spleen were weighed. Leucocytes and
thrombocytes were counted electronically.
Haemoglobin concentration was measured by the
haemoglobin cyanide spectrophotometrical assay.
Plasma vitamin B12 and folic acid were determined
simultaneously, essentially as described by Gutcho
& Mansbach (1977). Methyltetrahydrofolate was
used as a folate standard. Normal values for organ
weights, haematological parameters, plasma folate
and vitamin B12 concentrations were derived from
at least 12 comparable non-leukaemic Brown
Norway rats.
Deoxyuridine suppression test
This test is used to evaluate the metabolic
inactivation of vitamin B12 [3H]-thymidine
incorporation in DNA is measured with and
without added deoxyuridine. Deoxyuridine is able
to suppress incorporation of [3H]-thymidine very
significantly if it can be converted to thymidine by
folate-dependent methylation. This suppression is
decreased in bone marrow cells as a result of folate
or vitamin B12 deficiency, and as a result of the
inactivation of methylcobalamin by nitrous oxide
(McKenna et al., 1980).
In this test, leukaemic spleen cells were used
(-5 x 106 per test) from rats of the various groups
in Experiment 2, as described above. In addition,
leukaemic rats were included who were similarly
treated for 1 day only (Day 16-17), after which
they were sacrificed. In some cases, cycloleucine
was added to the leukaemic cell suspensions used in
the test to compare in vitro and in vivo effects of
this drug. The test was carried out according to
Metz et al. (1968) with some modification as
described before (Kroes et al., 1984). Deoxyuridine
(Sigma Chemical Co., St Louis, USA), was used in
a concentration of 0.1mmol - 1. Incorporation of
[3H]-thymidine (-0.3yCi per test, specific activity
25Cimmol-1, from Amersham International, UK),
is expressed as a percentage of the maximum
incorporation in each case, obtained by omitting
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Results
In each of the two experiments, four groups of
leukaemic rats were compared: one untreated
(controls), one treated with nitrous oxide, one
treated with cycloleucine, and one group treated
with both agents. Data on leukaemic growth in
these groups can be found in Tables I and II. All
rats survived until termination of the experiments,
except for one untreated rat in Experiment 2, dying
spontaneously a few hours before. Organ weights of
this rat have been included in the results.
The treated rats had reduced spleen and liver
weights (Table I) and reduced leukocyte counts
(Table II), compared to the untreated controls.
With Wilcoxon's non-parametric rank sum rest,
applied to the values of individual rats in both
experiments, these differences are statistically
significant (P<0.01). Combined treatment resulted
in the strongest inhibition of leukaemic growth,
with an increase in organ weights of less than half
of control values, as shown in Figure 1. The
differences between groups treated with a single
agent, and groups with combined treatment are
also statistically significant using Wilcoxon's test
(P<0.01).
No significant difference was observed between
the two groups treated with nitrous oxide or
cycloleucine alone. In fact, after preliminary
experiments, the lowest dose of cycloleucine was
selected which produced inhibition of growth about
comparable to nitrous oxide exposure alone. This
would facilitate recognition of a potentiating effect
after combined treatment and minimize possible
side effects of cycloleucine. With regard to the
haematological values shown in Table II, platelet
counts and haemoglobin values do not suggest
adverse effects of treatment on normal
haematopoiesis. Although all animals remained
thrombopenic, haemoglobin values showed a small
increase with treatment and were highest after
combined treatment. These differences were,
however, not statistically significant.
Treatment with N20, as in these experiments, is
Table I Effects of treatment on leukaemic infiltration in spleen and li'ver, and on body weight
Spleen weighta Liver weightb Body weight
Experiment 1 Experiment 2 Experiment I Experiment 2 Experiment 1+2
Treatment g±s.e. g+s.e. g±s.e. g±s.e. % change
None (controls) 4.52+0.18 4.49+0.15 21.38+0.60 20.54+1.58 -1.0
Cycloleucine 3.77+0.13 4.04+0.13 16.79+0.54 16.95+0.65 +0.2
Nitrous oxide 3.57+0.14 3.34+0.23 18.81 +0.30 15.50+0.93 -5.9
Cycloleucine and
nitrous oxide 2.32+0.08 2.42+0.05 13.04+0.54 13.48+0.51 -4.1
All treatment groups in both experiments consisted of 4 rats.
s.e. =standard error of the mean in each group.
anormal spleen weight in comparable non-leukaemic Brown-Norway rats: 0.45+0.07g.
bnormal liver weight in comparable non-leukaemic Brown Norway rats: 8.25+0.99g.
Table II Effects of treatment on haematological values
Leukocytesa Thrombocytesb Haemoglobin
Experiment 1 Experiment 2 Experiment 1+2 Experiment 1+2
Treatment 1091-1 +s.e. 1091- I +s.e. 1091- 1 +s.e. mmol/- I +s.e.
None (controls) 32.7+2.3 19.2+1.2 81 + 13 8.0+0.2
Cycloleucine 30.3 +3.9 11.8+0.6 94+ 13 8.7+0.1
Nitrous oxide 10.2+0.7 8.9+1.4 60+ 5 8.2+0.3
Cycloleucine and
nitrous oxide 5.3+0.3 5.2+0.6 61+ 8 9.2+0.1
All treatment groups in both experiments consisted of 4 rats.
s.e. =standard error of the mean in each group.
anormal value of leukocyte count in Brown Norway rats: 3.7+0.3 1091-.
bnormal value of thrombocyte count in Brown Norway rats: 790+22.1091-796 A.C.M. KROES et al.
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Figure 1 The percentages of increase in weight are indicated of (a) spleen and (b) liver in leukaemic rats,
relative to mean normal weights of spleen: 0.45g and liver: 8.25g in comparable non-leukaemic Brown
Norway rats. Data of Experiments 1 and 2 are combined. Each group consists of 8 rats. S.e.m. are indicated.
well tolerated by rats, without a noticeable
influence on consciousness. A limited loss of body
weight is observed, which is not aggravated by
cycloleucine (Table I).
Plasma concentrations of vitamin B12 and folic
acid as determined in the various groups of both
experiments, are shown in Figure 2. In untreated
leukaemic rats a strong increase in plasma levels of
vitamin B12 is found, whereas decreases are
observed after treatment. A pronounced effect of
nitrous oxide is evident, in particular when
compared with the effect of cycloleucine. Combined
treatment resulted in the lowest levels of vitamin
B12. Folic acid levels are low in untreated rats,
with treatment resulting in higher levels. In this
case, no differences are observed between the
various treatments.
Results of deoxyuridine suppression tests are
presented in Figure 3. In this test, higher values are
caused by a reduced suppressive effect of
deoxyuridine on the incorporation of [3H]-
thymidine, which is indicative of impaired de novo
synthesis of thymidine. Figure 3(a) shows
suppression values, obtained with leukaemic spleen
cells from rats of the four groups in Experiment 2.
Although the differences are small, they are
suggestive of a limited increase in suppression
values after N20 or cycloleucine as single
treatments, with a more severe disturbance after
combined treatment. These values, however, were
obtained 12 days after the initiation of treatment in
Experiment 2. In this period, the level of
cycloleucine may be appreciably reduced, although
this agent in normal rats has a plasma half life of
about 22 days (Christensen & Clifford, 1962).
Therefore, in a separate experiment leukaemic
spleen cells were used of rats 1 day after the
administration of cycloleucine (Figure 3b). This
resulted in a more pronounced effect after
combined treatment. About the same values were
observed with in vitro addition of cycloleucine to
leukaemic cell suspensions of untreated rats and
rats treated with N20. At a concentration of
1 mmol -1, effects on the deoxyuridine suppression
test are comparable with in vivo administration of
50mgkg-1 cycloleucine.
Discussion
Exposure to N20 is known to cause a selective and
virtually complete inhibition of the methyl-
cobalamin-dependent enzyme methionine synthetase
(Deacon et al., 1980). This enzyme is essential
both for the generation of tetrahydrofolate (THF)
and the synthesis of methionine (see Figure 4).
The disturbance of folate metabolism, and in
particular of folate-dependent de novo synthesis of
thymidine, is considered to be primarily responsible
for theimpairment ofcellular proliferation caused by
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Figure 2 Plasma levels of (a) vitamin B12 and (b) folic acid in leukaemic rats of Experiments 1 and 2.
Values in normal (non-leukaemic) rats are also shown. S.e.m. are indicated.
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Figure 3 Deoxyuridine suppression values in leukaemic cells: (a) from four groups of two rats each, 12 days
after the administration of cycloleucine and initiation of nitrous oxide exposure; (b) from four rats, after
treatment for 1 day, with cycloleucine administered in vivo (columns 2 and 4), and cycloleucine added in vitro
to leukaemic cell suspensions (columns 5 and 6). Each value is the mean of triple incubations, with a maximal
difference between estimations of 10%. dU: deoxyuridine.
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ethionine synthetase
rethionine adenosyltransferase
ethylene-THF reductase
ymidylate synthetase
Figure 4 Relations between the reactions discussed in the text, with indication of enzymes and inhibitors.
N20: nitrous oxide; THF: tetrahydrofolate; SAM: S-adenosylmethionine.
nitrous oxide. However, it appears that methionine
metabolism is also involved in this effect. From
metabolic studies in rats it has become evident that
the disturbed folate metabolism on N20 exposure
can be completely restored by the administration of
methionine (Eells et al., 1982). An explanation for
this effect is the established ability of methionine,
after its conversion to S-adenosylmethionine
(SAM), to inhibit the enzyme 5,10-methylene-THF
reductase (Kutzbach & Stokstad, 1967). This will
prevent the detrimental accumulation of the
substrate of methionine synthetase, 5-methyl-THF,
which is caused by nitrous oxide (Figure 4). An
alternative explanation is to assume direct
activation of methionine synthetase by SAM
(Billings et al., 1981). Thus, it appears that SAM
antagonizes the effect of nitrous oxide on folate
metabolism. This conclusion is supported by other
reports (Perry et al., 1983; Sourial & Amess, 1983),
while it is interesting to note that methionine also
protects against specific neurological disorders
caused by nitrous oxide in some species (Scott et
al., 1981; Van der Westhuyzen et al., 1982).
In this study, an effect is demonstrated which can
be considered a direct consequence of the same
interaction. The effects of nitrous oxide alone on
leukaemic growth in vivo appear to be limited to
the extent which is achieved in this study and in
previous work (Kroes et al., 1984). In the present
study, however, it is shown that the inhibitory
effects on leukaemia can be increased by an
additional reduction of SAM synthesis, which is
induced by cycloleucine. A combination of nitrous
oxide exposure with the administration of
cycloleucine resulted in the strongest reduction of
leukaemic proliferation. With regard to spleen
weight, the amount of this reduction seemed to be
even more than the added effects of both agents
when given separately. This is also reflected in the
deoxyuridine suppression test, which measures the
capacity of de novo synthesis of thymidine. In this
test, the effect of nitrous oxide is enhanced by
cycloleucine: this applies both to the in vivo
combination of these two agents and the in vitro
addition of cycloleucine to leukaemic cells of rats
treated with nitrous oxide.
The most likely explanation of this synergistic
action therefore is further impairment of folate
metabolism. The cytostatic properties of cyclo-
leucine generally are attributed to its inhibition of
SAM-dependent methylation reactions (Caboche &
Hatzfeld, 1978). Although it was recently shown
that N20 also decreases tissue levels of SAM (Lumb
et al., 1983; Makar & Tephly, 1983), it remains
uncertain to what extent this effect directly con-
tributes to the inhibition of cellular proliferation.
In this respect, the impairment of thymidine
synthesis is an established mechanism. It should not
be excluded that N20 and cycloleucine mutually
can potentiate distinctive cytostatic effects.
Peripheral leukocyte counts clearly are lowest
with combined treatment. It appears that nitrous
oxide more effectively reduces peripheral
leukocytes, when compared with cycloleucine as a
single agent.
Nitrous oxide and cycloleucine also appear quite
different with regard to their effects on plasma
levels of vitamin B12. We have previously shown
homocysteine
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that a continuous rise of plasma vitamin B12 is a
feature of this leukaemia in rats (Kroes et al.,
1984). The reduction of leukaemic growth, as
caused by cycloleucine, is not very effective in
decreasing vitamin B12 levels. Nitrous oxide
treatment, however, with about the same inhibition
of leukaemic growth, caused a striking fall in
plasma vitamin B12 to subnormal levels. This is
evidence of a specific effect of this agent, which
oxidizes the methylcobalamin coenzyme. Reduced
vitamin B12 levels in plasma with prolonged N20
exposure were already reported in fruit bats (Van
der Westhuyzen et al., 1982), and, remarkably, in
the first case of human leukaemia treated with N20
(Lassen & Kristensen, 1959). Kondo et al. (1981)
showed that with N20 exposure analogues of
cobalamin are formed which are rapidly excreted,
resulting in a depletion of vitamin B12.
Folic acid levels were low in untreated leukaemic
rats, which is probably related to the increased
demands of rapid cellular proliferation (Kelly et al.,
1983). In all treated groups folate levels were
increased, and with regard to N20 treatment this
effect has been observed before (Lumb et al., 1981).
This is explained by the blockade in folate
metabolism, with a reduction of cellular uptake of
folates and a consequent accumulation in plasma.
Cycloleucine causes the same increase in folate
levels, however, and this supports the presumed
role of SAM in the regulation of folate metabolism,
as discussed before. Finally, it should be noted that,
with a low dose of cycloleucine as used in this
study, no adverse effects were apparent when
comparing treated and untreated rats.
It can be concluded that it is possible to achieve
increased inhibition of leukaemic proliferation when
N20 is combined with a low dose of cycloleucine,
an inhibitor of SAM synthesis. This effect supports
a role of SAM in modulating the effects of N20,
and should stimulate further research to establish
cobalamin-dependent metabolism as an additional
target in cancer chemotherapy. On the other hand,
these results suggest that cycloleucine can be used
more effectively than in the toxicity limited dosages
used before, when it is combined with N20, an
agent which has the additional advantage of
notable analgesic properties.
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